The Pharmaceutical Journal
Vol 280 No 7490 p205
23 February 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Sebivo neuropathy warning

New warnings about the risk of peripheral neuropathy in patients with chronic hepatitis B who are being treated with Sebivo (telbivudine) are to be included in Sebivo’s product information following a recommendation from the European Medicines Agency.
(PDF 40K)

The agency says that patients should be monitored for signs of peripheral neuropathy and treatment options reconsidered if the condition is suspected.